ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study

Authors:
  • STS.-C. Tang
    S.-C. Tang
  • PKP. Kumthekar
    P. Kumthekar
  • ABA.J. Brenner
    A.J. Brenner
  • SKS. Kesari
    S. Kesari
  • DPD. Piccioni
    D. Piccioni
  • CAC.K. Anders
    C.K. Anders
  • JCJ.A. Carillo
    J.A. Carillo
  • PCP. Chalasani
    P. Chalasani
  • PKP. Kabos
    P. Kabos
  • SPS.L. Puhalla
    S.L. Puhalla
  • AGA. Garcia
    A. Garcia
  • KTK. Tkaczuk
    K. Tkaczuk
Publisher website
Google Scholar
Abstract
Background: ANG1005 is a novel taxane derivative, consisting of 3 paclitaxel molecules covalently linked to Angiopep-2, a peptide designed to utilize the LRP-1 transport system to cross the BBB/BCB and to penetrate malignant cells. We conducted an open label phase II clinical study to test its activity in metastatic breast cancer (BC) patients with recurrent brain metastasis (BM), including BCBM patients with newly diagnosed leptomeningeal carcinomatosis (LC).